Strand Life Sciences launches South Asia’s first Olink® Explore HT Proteomics Service

Bengaluru-based Strand Life Sciences, a subsidiary of Reliance Industries Limited, has announced the launch of its advanced proteomics capabilities powered by Olink™ Explore HT, marking a key milestone in expanding large-scale multi-omics research in South Asia.

Next-generation proteomics enables the simultaneous analysis of thousands of proteins from a single sample, supporting deeper insights into disease biology, biomarker discovery, and precision medicine.

As part of this milestone, Strand has successfully completed a proteomics project for a biopharma partner involving patients with chronic kidney disease, demonstrating the platform’s potential in translational research and clinical studies.

Olink Explore HT enables the measurement of over 5,400 protein biomarkers from just 2 µL of sample, allowing Strand to deliver integrated proteomics, genomics, and clinical insights for advanced research and drug discovery.

Strand can now support the generation of large, multi-modal datasets across diverse and clinically relevant populations in India, broader South Asia, and the Middle East. Through its extensive network of clinical partners, the company enables studies across multiple therapeutic areas, including oncology, nephrology, metabolic diseases, and rare disorders.